Bicyclo Ring System Having The Hetero Ring As One Of The Cyclos (e.g., Chromones, Etc.) Patents (Class 514/456)
Coumarins (including hydrogenated) (Class 514/457)
Tocopherols (e.g., vitamin e, etc.) (Class 514/458)
  • Method for Treating Skin with Retinoids and Retinoid Boosters
    Publication number: 20140050676
    Abstract: A skin care product comprising from about 0.001% to about 10% of a retinoid, in combination with 0.0001% to about 50% of a combination of retinoid boosters.
    Type: Application
    Filed: February 11, 2013
    Publication date: February 20, 2014
    Applicant: Conopco, Inc., d/b/a UNILEVER
    Inventor: Conopco, Inc., d/b/a UNILEVER
  • REGULATOR, PHARMACEUTICAL COMPOSITION ENCOMPASSING THE REGULATOR AND APPLICATION THEREOF
    Publication number: 20140051743
    Abstract: The present disclosure is directed to a regulator, a pharmaceutical composition encompassing the regulator and the application thereof The regulator modulates the expression integrins and/or EMP2, and is employed for treating integrins-associated and/or EMP2-associated diseases.
    Type: Application
    Filed: May 14, 2013
    Publication date: February 20, 2014
    Applicant: NATIONAL CHENG KUNG UNIVERSITY
    Inventor: National Cheng Kung University
  • Compositions and Methods for Treating Myotonic Dystrophy Type 1
    Publication number: 20140051709
    Abstract: Disclosed is a compound for treatment of Myotonic Dystrophy type 1 having the formula: Wherein X is selected from the group consisting of O, N, C, or S, Y is a homo- or heteroatomic 5-membered ring comprising one or more atoms selected from the group consisting of N, O, S, and C, Z is an optionally substituted aryl group or optionally substituted heteroaryl, including but not limited to halogenated benzenes, pyridines, substituted benzene, substituted pyridine, R2=hydroxy, acyl, alkoxyl, esters, ethers, cyclic ethers, and lactones, R3=H, alkyl, an optionally substituted alkyl, aliphatic ether, ester, cyclic unsaturated and aromatic ring groups, and R1, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, alkyl, and alkoxyl or a pharmaceutically or cosmetically acceptable salt, solvate, or hydrate thereof.
    Type: Application
    Filed: August 16, 2012
    Publication date: February 20, 2014
    Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Sita REDDY, Lucio Comai, Nouri Neamati
  • FLAVANOL AND CAROTENOID COMPOSITIONS
    Publication number: 20140045932
    Abstract: This invention relates to compositions containing polyphenols, for example, cocoa polyphenols such as flavanols and their related oligomers, and methods for treating abnormalities in gap junctional communication of cells, such as cancer, heart arrhythmia, neuro-degenerative diseases and cognitive dysfunction.
    Type: Application
    Filed: October 23, 2013
    Publication date: February 13, 2014
    Applicant: MARS, INCORPORATED
    Inventor: Helmut SIES
  • POLYPHENOL PROTEASOME INHIBITORS, SYNTHESIS, AND METHODS OF USE
    Publication number: 20140045931
    Abstract: The present invention relates to synthetic green tea derived polyphenolic compounds, their modes of syntheses, and their use in inhibiting proteasomal activity and in treating cancers. The present invention is also directed to pharmaceutical compositions useful in methods of inhibiting proteasomes and of treating cancers.
    Type: Application
    Filed: October 18, 2013
    Publication date: February 13, 2014
    Applicant: THE HONG KONG POLYTECHNIC UNIVERSITY
    Inventors: Q. PING DOU, TAK-HANG CHAN, DAVID M. SMITH
  • NUTRITIONAL COMPOSITIONS HAVING ALPHA-HICA AND CITRULLINE
    Publication number: 20140044685
    Abstract: Nutritional compositions for maximizing muscle protein synthesis while minimizing the catabolism of muscle proteins and methods of using same are provided. In this manner, the nutritional compositions may provide for retention of lean body mass, which helps to avoid loss of independence and functionality, as well as to improve quality of life especially in the elderly at risk of sarcopenia and frailty. The nutritional compositions include ?-hydroxyisocaproic acid and citrulline. The composition may include other functional ingredients such as, but not limited to whey protein including whey protein micelles, prebiotic fibers, ?-keto-glutarate, eicosapentaenoic acid, L-carnitine, nucleotides, and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided.
    Type: Application
    Filed: April 18, 2012
    Publication date: February 13, 2014
    Applicant: NESTEC S.A.
    Inventors: Norman Alan Greenberg, Denis Breuille, Zamzam Kabiry (Fariba) Roughead, Doug Bolster, Jennifer Mager
  • ASSAY FOR ARGINYL HYDROXYLASE ACTIVITY
    Publication number: 20140045930
    Abstract: The present invention relates to assays for monitoring activity of YcfD activity, in particular, to assays for identifying modulators of YcfD activity. The present invention also relates to the use of YcfD inhibitors as antibiotics. The invention also relates to methods for introducing hydroxyarginine residues into proteins.
    Type: Application
    Filed: January 30, 2012
    Publication date: February 13, 2014
    Inventors: Christopher Joseph Schofield, Chia-Hua Ho, Alexander Wolf, Wei Ge
  • POLYPHENOL/THEANINE COMPOSITIONS
    Publication number: 20140045928
    Abstract: Disclosed herein are compositions comprising tea derived components which are useful in reducing the incidence of cold and/or flu in a subject. Specifically exemplified herein are compositions comprising predetermined amounts of L-theanine and EGCG, and methods of using same.
    Type: Application
    Filed: June 18, 2013
    Publication date: February 13, 2014
    Inventors: Jeffrey Walters, Jack F. Bukowski
  • CHROMAN-DERIVED ANTI-ANDROGENS FOR TREATMENT OF ANDROGEN MEDIATED DISORDERS
    Publication number: 20140045929
    Abstract: Methods for the prevention and/or alleviation of androgen-mediated disorders treatable by administering a chroman-derived anti-androgen compound are provided by the present invention. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived anti-androgen compounds useful in the prevention and/or alleviation of androgen-mediated disorders, particularly prostate cancer.
    Type: Application
    Filed: August 14, 2013
    Publication date: February 13, 2014
    Applicant: Wisconsin Alumni Research Corporation
    Inventors: Todd A. Thompson, George Wilding
  • METHODS FOR REGULATING SIRTUIN GENE EXPRESSION
    Publication number: 20140039047
    Abstract: The invention provides methods useful for regulating sirtuin gene expression, mimicking caloric restriction, preventing and treating Alzheimer's disease, increasing longevity and retarding aging in an animal. The methods comprise administering one or more isoflavones to the animals, preferably in amounts of from about 0.001 to about 10 g/kg/day.
    Type: Application
    Filed: March 26, 2012
    Publication date: February 6, 2014
    Inventors: Yuanlong Pan, Rondo Paul Middleton
  • PHARMACEUTICAL COMPOSITIONS COMPRISING CANNABIGEROL
    Publication number: 20140039043
    Abstract: The present invention relates to the use of cannabigerol (CBG) type compounds and derivatives thereof in the treatment of mood disorders.
    Type: Application
    Filed: April 24, 2013
    Publication date: February 6, 2014
    Applicant: GW Pharma Limited
    Inventor: GW Pharma Limited
  • METHODS AND COMPOSITIONS SUITABLE FOR PREVENTING AND TREATING HYPERLEPTINEMIA
    Publication number: 20140037583
    Abstract: The invention provides methods and compositions suitable for preventing and treating hyperleptinemia, preventing and treating insulin resistance, preventing and treating cardiovascular disease, preventing and treating obesity, preventing and treating hyperlipidemia, and preventing and treating hypertension in an animal. The methods comprise administering one or more isoflavones to the animal, preferably in amounts of from about 0.001 to about 10 g/kg/day.
    Type: Application
    Filed: April 17, 2012
    Publication date: February 6, 2014
    Inventors: Yuanlong Pan, Rondo Paul Middleton
  • LUTEOLIN AND DIOSMIN/DIOSMETIN AS NOVEL STAT3 INHIBITORS FOR TREATING AUTISM
    Publication number: 20140038913
    Abstract: The present invention includes methods for the treatment of autoimmune disorders such as autism, schizophrenia, and type 1 diabetes. Flavonoids, luteolin, diosmin, and diosmin's aglycone form, diosmetin, were found to inhibit activation/phosphorylation of STAT3 induced by IL-6 in cultured neuronal cells. Furthermore, mice treated with diosmin showed a significant reduction of autistic phenotype induced by IL-6 through inhibition of STAT3 activation.
    Type: Application
    Filed: October 4, 2013
    Publication date: February 6, 2014
    Applicant: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Jun Tan, Deyan Luo
  • COMPOSITION OF MONOTERPENOIDS HAVING BACTERICIDAL PROPERTIES
    Publication number: 20140039045
    Abstract: A composition having bactericidal properties comprising; (a) 30%-80% of at least one compound having the formula (I) and (b) 10% to 40% of at least one compound of formula (II)
    Type: Application
    Filed: August 19, 2011
    Publication date: February 6, 2014
    Inventor: Max Reynolds
  • COMPOSITIONS AND PRODUCTS CONTAINING S-EQUOL, AND METHODS FOR THEIR MAKING
    Publication number: 20140039046
    Abstract: A composition for use in making commercial food and skin products comprising 5-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism.
    Type: Application
    Filed: August 28, 2013
    Publication date: February 6, 2014
    Applicants: CHILDREN'S HOSPITAL MEDICAL CENTER, AUSTRALIAN HEALTH & NUTRITION ASSOCIATION LIMITED
    Inventors: Kenneth David Reginald SETCHELL, Sidney John COLE
  • Hydroxylated Polymethoxyflavone Compositions
    Publication number: 20140039044
    Abstract: Provided herein are compositions enriched in polyhydroxylated polymethoxyflavones useful as dietary supplements, food additives, pharmaceutical compositions, nutraceutical compositions and cosmetic compositions.
    Type: Application
    Filed: July 5, 2013
    Publication date: February 6, 2014
    Applicants: WLLGEN, INC., RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Chi-Tang Ho, Shiming Li, Min-Hsiung Pan, Chih-Yu Lo, Slavik Dushenkov
  • Compositions and Methods for Treating Bruises
    Publication number: 20140031422
    Abstract: A composition for the treatment of bruising is disclosed. The composition can include an antioxidant, one or more citrus flavanoids, as active agents along with a pharmaceutically acceptable excipient or filler. The compositions are nutriceutical formulations having the capacity to reduce the number of bruises that occur over time and that reduce the healing time of bruises. The compositions are preferably in tablet form for oral consumption one or more times per day. A method of reducing bruising is also disclosed in which a patient in need of a treatment for bruising or at risk of developing bruises is identified. The composition can then be administered orally to the patient.
    Type: Application
    Filed: September 26, 2013
    Publication date: January 30, 2014
    Applicant: M. ALPHABET, LLC
    Inventors: Howard Fein, Mindy B. Berlin
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING INFLUENZA VIRUSES REPLICATION
    Publication number: 20140030224
    Abstract: The present invention relates to methods and pharmaceutical compositions for inhibiting influenza virus replication. More particularly, the present invention relates to a compound selected from the group consisting of Gemcitabine, Obatoclax Mesylate, Docetaxel, HA-14, Alsterpaullone, GSK3B inhibitor VIII, GSK3B inhibitor XV, Indirubin 3?- monoxime, L glutathione reduced, Fluocinolone acetonide, Tirofiban, Topotecan hydrochloride, Clofarabine, Vinblastine, Menadione Crystalline and derivatives or analogues thereof for use in the treatment of an influenza infection in a subject in need thereof.
    Type: Application
    Filed: April 10, 2012
    Publication date: January 30, 2014
    Applicant: UNIVERSITÉ CLAUDE BERNARD - LYON 1
    Inventors: Vincent Lotteau, Benoit De Chassey, Patrice Andre, Laurene Meyniel-Schicklin, Anne Aublin-Gex
  • NOVEL PROCESS FOR SYNTHESIS OF POLYPHENOLS
    Publication number: 20140031421
    Abstract: The present invention provides synthetic processes for preparing racemic and/or optically pure epicatechin, epigallocatechin and related polyphenols as such or as their variously functionalized derivatives. A principle objective of the disclosure is to provide a new and useful method of synthesis to obtain polyphenols in isomerically pure and/or racemic forms.
    Type: Application
    Filed: January 24, 2012
    Publication date: January 30, 2014
    Applicant: SPHAERA PHARMA PTE. LTD.
    Inventors: Sundeep Dugar, Dinesh Mahajan, Pantelis Peter Giannousis, Vijay Singh, Kamal Kishore Kapoor
  • INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES
    Publication number: 20140031338
    Abstract: The present invention relates to compounds, their use in the treatment or the prevention of viral disorders, including HIV.
    Type: Application
    Filed: April 13, 2012
    Publication date: January 30, 2014
    Applicant: LABORATOIRE BIODIM
    Inventors: Sophie Chasset, Francis Chevreuil, Benoit Ledoussal, Frédéric Le Strat, Richard Benarous
  • COMPOSITION AND METHOD FOR TREATING DIABETES AND METABOLIC DISORDERS
    Publication number: 20140031420
    Abstract: A composition and method for treating diabetes and metabolic disorders, and for achieving weight loss in a subject comprising a combination of naturally occurring compounds is provided.
    Type: Application
    Filed: August 7, 2013
    Publication date: January 30, 2014
    Applicant: ATM Metabolics LLC
    Inventors: Milton Joseph AHRENS, Daryl Lee Thompson
  • Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
    Patent number: 8637569
    Abstract: The subject invention relates to novel soluble forms of planar ring structured organic compounds including flavonoids, and their production. The invention also includes the use of these novel formulations of planar ring structured organic compounds in the preparation of formulations and products. The invention also relates to a wide variety of applications of the formulations of the invention. The subject invention includes novel soluble forms and various formulations of flavonoids. Further, the invention includes novel methods of manufacturing the flavonoid formulations. The invention also relates to a wide variety of applications of the flavonoid formulations.
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: January 28, 2014
    Assignee: API Genesis, LLC
    Inventor: Philip J. Birbara
  • Method of Ameliorating Clotting Pathologies and Related Materials and Methods
    Publication number: 20140024624
    Abstract: Methods for reducing blood clotting in a subject are provided, including methods to reduce the risk of and/or treat blot clotting pathologies. Also provided are compositions useful to reduce the risk or treat blood clotting pathologies.
    Type: Application
    Filed: March 15, 2013
    Publication date: January 23, 2014
    Applicant: THE OHIO STATE UNIVERSITY
    Inventors: Chandan K. Sen, Sashwati Roy, Savita Khanna, Cameron Rink
  • Method for making insect repellent composition
    Patent number: 8633325
    Abstract: Dihydronepetalactone, a minor natural constituent of the essential oil of catmints (Nepeta spp.) such as Nepeta cataria, has been identified as an effective insect repellent compound. Synthesis of dihydronepetalactone may be achieved by hydrogenation of nepetalactone, the major constituent of catmint essential oils. This compound, which also has fragrance properties, may be used commercially for its insect repellent properties, and methods for making an composition thereof are disclosed.
    Type: Grant
    Filed: June 8, 2009
    Date of Patent: January 21, 2014
    Assignee: E I du Pont de Nemours and Company
    Inventors: David L. Hallahan, Leo Ernest Manzer
  • Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
    Patent number: 8633241
    Abstract: The present invention provides an improved process for the synthesis of nebivolol or its pharmaceutically acceptable salts, more particularly hydrochloride salt of formula (I). The present invention further provides a new Form T1 of nebivolol and its pharmaceutically acceptable salts. The present invention also provides pharmaceutical compositions and process for the preparation of a solid oral dosage form of nebivolol hydrochloride of formula (I), without the use of wetting agent, and optionally using binder and/or disintegrant.
    Type: Grant
    Filed: April 9, 2013
    Date of Patent: January 21, 2014
    Assignee: Forest Laboratories Holdings, Limited
    Inventors: Srinivasarao Veeravenkata Attanti, Hasmukh Mathurbhai Patel, Sunil Sadanand Nadkarni
  • MULTIPARTICULATE L-MENTHOL FORMULATIONS AND RELATED METHODS
    Publication number: 20140017324
    Abstract: An L-menthol-containing multiparticulate formulation includes a plurality of individual enteric coated cores containing L-menthol from an at least 80% pure L-menthol source. The enteric coated cores are effective to release at least about 35% of the L-menthol within about two hours, and at least about 80% of the L-menthol within about eight hours after being placed in an environment having a pH of 5 to 8. The L-menthol multiparticulate formulation can be used to treat gastrointestinal disorders.
    Type: Application
    Filed: September 23, 2013
    Publication date: January 16, 2014
    Applicant: ZX PHARMA, LLC
    Inventors: SYED SHAH, FRED HASSAN, DANIEL HASSAN, SARAH HASSAN
  • Pro-drug Compounds
    Publication number: 20140011773
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof: The compound is used in pharmaceutical compositions and in a method of treatment of a disease or medical condition which benefits from inhibition of gap junction activity by administering to a subject suffering from such disease or condition.
    Type: Application
    Filed: July 3, 2013
    Publication date: January 9, 2014
    Inventors: Edward Savory, Martyn Pritchard, Mike Ashwood
  • COMPOSITIONS AND METHODS OF TREATMENT WITH PROANTHOCYANIDIN POLYMER ANTIDIARRHEAL COMPOSITIONS
    Publication number: 20140011869
    Abstract: Pharmaceutical compositions containing a proanthocyanidin polymer composition which are useful for the treatment and prevention of secretory diarrhea are provided. The invention specifically relates to pharmaceutical formulations of a proanthocyanidin polymer composition which has been isolated from a Croton spp. or a Calophyllum spp. In particular, the invention relates to a formulation of a proanthocyanidin polymer composition which protects the composition from the effects of stomach acid after oral administration, particularly to those formulations which are enteric coated. The invention also relates to methods of producing a directly compressible proanthocyanidin polymer composition, as well as compositions containing the directly compressible proanthocyanidin polymer composition.
    Type: Application
    Filed: September 11, 2013
    Publication date: January 9, 2014
    Inventors: Edward James Rozhon, Atul S. Khandwala, Akram Sabouni, Gul P. Balwani, Jody Wai-Han Chan, David F. Sesin
  • FITNESS ASSAY AND ASSOCIATED METHODS
    Publication number: 20140011815
    Abstract: The present invention provides an assay for determining the biochemical fitness of a biochemical species in a mutant replicating biological entity relative to its predecessor. The present invention further provides a continuous fluorogenic assay for measuring the anti-HIV protease activity of protease inhibitor. The present invention also provides a method of administering a therapeutic compound that reduces the chances of the emergence of drug resistance in therapy.
    Type: Application
    Filed: July 2, 2013
    Publication date: January 9, 2014
    Inventors: John W. Erickson, Sergei V. Gulnik, Hiroaki Mitsuya, Arun E. Ghosh
  • Boron-containing small molecules as anti-protozoal agent
    Patent number: 8623911
    Abstract: This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: January 7, 2014
    Assignee: Anacor Pharmaceuticals, Inc.
    Inventors: Robert T. Jacobs, Daitao Chen, Matthew Orr, Jacob J. Plattner
  • Isoflavones for treating mucopolysaccharidoses
    Patent number: 8623910
    Abstract: A method of treatment of mucopolysaccharidosis, the method including administering to a patient in the need of such treatment—a therapeutically effective amount of a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition including a pharmaceutically acceptable excipient; and a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof, the natural isoflavone, the derivative thereof, or the pharmaceutically acceptable salt thereof being in a therapeutically effective amount for the treatment of mucopolysaccharidosis.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: January 7, 2014
    Assignee: Instytut Farmaceutyczny
    Inventors: Grzegorz Grynkiewicz, Grzegorz Wegrzyn, Barbara Szechner, Wieslaw Szeja, Anna Tylki-Szymanska, Alicja Wegrzyn, Joanna Jakobkiewicz-Banecka, Sylwia Baranska, Barbara Czartoryska, Ewa Piotrowska
  • STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS
    Publication number: 20140005135
    Abstract: Disclosed is a stable liquid formulation for parenteral injection comprising a biocompatible non-aqueous solvent and a small molecule drug, or a salt thereof, solubilized within the non-aqueous solvent, wherein the liquid formulation comprises less than 10% by weight residual water, and wherein the volume of the liquid formulation to be parenterally injected is from 0.1 ?l to 3 ml.
    Type: Application
    Filed: March 14, 2013
    Publication date: January 2, 2014
    Applicant: XERIS PHARMACEUTICALS, INC.
    Inventors: Steven J. Prestrelski, Nancy Scott
  • Cromolyn derivatives and related methods of imaging and treatment
    Patent number: 8617517
    Abstract: Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula (I), or formula (II); wherein X is OH, C1-C6 alkoxyl, 18F, or 19F; Y and Z are independently selected from a C1-C6 alkyl, CpC6 alkoxyl, halogen, un-substituted or C1-C6 substituted amine, 18F, 19F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H, X is not OH.
    Type: Grant
    Filed: January 29, 2010
    Date of Patent: December 31, 2013
    Assignee: The General Hospital Corporation
    Inventors: David R. Elmaleh, Timothy Shoup
  • SMALL MOLECULE MODULATORS OF THE COLD AND MENTHOL RECEPTOR TRPM8
    Publication number: 20130345300
    Abstract: The present invention relates to the use of compounds which are capable of producing a cooling sensation when they are brought into contact with the human body. In particular, the present invention relates to the use of compounds modulating TRPM8, and optionally to the use of compounds selectively exhibiting agonist activity at the TRPM8 channel. Such compounds have applications in many fields, particularly in oral and personal hygiene products and foodstuffs, but also in pharmaceutical composition products, cosmetics, textile products and packaging products. The present invention further relates to products containing such compounds and to the medical use of such compounds.
    Type: Application
    Filed: March 8, 2012
    Publication date: December 26, 2013
    Applicant: B.R.A.I.N. Biotechnology Research and Information Network AG
    Inventors: Michael Krohn, Holger Zinke
  • TRPV1 ANTAGONISTS
    Publication number: 20130345255
    Abstract: Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, prodrugs, or combinations thereof, wherein X1, L, Rx, Ry, Rz, R1, R2, A, m, n, p, q, and r are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Application
    Filed: June 20, 2013
    Publication date: December 26, 2013
    Inventors: Arthur Gomtsyan, Jerome Daanen, Michael E. Kort, Philip R. Kym, Eric A. Voight, Kevin R. Woller
  • Method for Mediating Dopamine Receptor-Driven Reacidification of Lysosomal pH
    Publication number: 20130338145
    Abstract: Provided is a method of treating or preventing age-related macular degeneration (AMD) or Stargardt's disease in a patient subject to, or symptomatic of the disease, whereby normal lysosomal pH (pHL) of compromised retinal pigment epithelium (RPE) cells of the eye is restored, or abnormally elevated pHL is reacidified, thus decreasing or preventing damaging accumulations of lipofuscin debris or photoreceptor waste products. Further provided is a method for restoring photoreceptors to the eye of a patient subject to, or symptomatic of reduced photoreceptor activity or lipofuscin accumulation in RPE cells. By these methods D5 dopamine receptor (D5DR) agonists are administered to stimulate D5DR activity of compromised RPE cells, thereby regulating and reacidifying lysosomal pH (pHL) by a D5 dopamine receptor-(D5DR)-mediated pathway, without altering baseline maintenance.
    Type: Application
    Filed: March 15, 2013
    Publication date: December 19, 2013
    Inventors: Claire H. Mitchell, Alan M. Laties
  • CAROTENOID PARTICLES AND USES THEREOF
    Publication number: 20130337068
    Abstract: This invention relates to the incorporation of bioactive cargo molecules into particles with carotenoids, such as lycopene. The incorporation of a cargo molecule into a carotenoid particle may for example increase the bioavailability of the cargo molecule in the bloodstream compared to other delivery systems. Carotenoid particles as described herein may be useful in the formulation of therapeutic and nutritional compounds for oral administration to individuals.
    Type: Application
    Filed: January 25, 2012
    Publication date: December 19, 2013
    Applicant: IP Science Limited
    Inventor: Ivan Petyaev
  • METHODS AND CELLS FOR IDENTIFYING RIG-I PATHWAY REGULATORS
    Publication number: 20130336929
    Abstract: Disclosed herein are methods for identifying compounds for the treatment of viral infection, including RNA viral infection and uses of the compounds as pharmaceutical compositions. The identified compounds modulate the RIG-I pathway in vertebrate cells.
    Type: Application
    Filed: February 23, 2012
    Publication date: December 19, 2013
    Inventors: Shawn P. Iadonato, Kristin Bedard
  • THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES
    Publication number: 20130338117
    Abstract: This invention provides methods of inhibiting replication of a poxvirus by contacting a poxvirus with a compound having formula I, formula XXI, formula XXXII, or formula XLI which in turn reduce, inhibit, or abrogate poxvirus DNA polymerase activity and/or its interaction with its processivity factor. Formula I, formula XXI, formula XXXII, or formula XLI can be utilized to treat humans and animals suffering from a poxvirus infection. Pharmaceutical compositions for treating poxvirus infected subjects are also provided.
    Type: Application
    Filed: August 27, 2013
    Publication date: December 19, 2013
    Applicant: The Trustees of the University of Pennsylvania
    Inventor: Robert P. RICCIARDI
  • TRPV1 antagonists
    Patent number: 8609692
    Abstract: Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: December 17, 2013
    Assignee: AbbVie Inc.
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, Jun Chen, Stanley DiDomenico, Jerome F. Daanen, Michael E. Kort, Philip R. Kym, Heath A. McDonald, Richard J. Perner, Robert G. Schmidt, Eric A. Voight
  • ?- and ?-diketones and ?-hydroxyketones as /?-catenin signaling pathway activators
    Patent number: 8609717
    Abstract: The present invention discloses ?-diketones, ?-diketones or ?-hydroxyketones or analogs thereof, that activate Wnt/?-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related to the differentiation and development of the central nervous system, comprising Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, comprising hair loss, hematopoiesis related diseases and tissue regeneration related diseases.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: December 17, 2013
    Assignee: Samumed, LLC
    Inventors: Sunil Kumar KC, David Mark Wallace, John Hood, Charlene F. Barroga
  • Methods of treating and/or suppressing insulin resistance
    Patent number: 8609695
    Abstract: Novel methods for the medical treatment and/or prevention of obesity, abdominal fat, and insulin resistance in susceptible warm-blooded animals including humans involves the administration of selective estrogen receptor modulators (SERMs). A combination of a SERM with an amount of estrogen or a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-ene-3b,17b-diol and compounds converted in vivo to one of the foregoing precursors or estrogen is also disclosed.
    Type: Grant
    Filed: March 10, 2003
    Date of Patent: December 17, 2013
    Assignee: Endorecherche, Inc.
    Inventors: Fernand Labrie, Yves Deshaies, Denis Richard, Celine Martel, Andre Marette
  • Chondropsin-class antitumor V-ATPase inhibitor compounds, compositions and methods of use thereof
    Patent number: 8609716
    Abstract: A composition comprising a substantially purified compound of the formula: in combination with at least one additional therapeutic agent, and methods of preventing or treating cancer and a condition treatable by the inhibition of vacuolar-type (H+)-ATPase.
    Type: Grant
    Filed: October 1, 2012
    Date of Patent: December 17, 2013
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Michael R. Boyd, Kirk R. Gustafson
  • Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
    Patent number: 8604222
    Abstract: The present invention provides an improved process for the synthesis of nebivolol or its pharmaceutically acceptable salts, more particularly hydrochloride salt of formula (I). The present invention further provides a new Form T1 of nebivolol and its pharmaceutically acceptable salts. The present invention also provides pharmaceutical compositions and process for the preparation of a solid oral dosage form of nebivolol hydrochloride of formula (I), without the use of wetting agent, and optionally using binder and/or disintegrant.
    Type: Grant
    Filed: August 1, 2005
    Date of Patent: December 10, 2013
    Assignee: Forest Laboratories Holdings Limited
    Inventors: Rakesh Sheth, Srinivasarao Veeravenkata Attanti, Hasmukh Mathurbhai Patel, Vinodkumar Gupta, Sunil Sadanand Nadkarni
  • SUBSTITUTED HETEROCYCLIC COMPOUNDS
    Publication number: 20130324525
    Abstract: The present invention relates to novel heterocyclic compounds and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (I): wherein Q1, Q2, R2, R3, R4, R5, and R6 are as described herein. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: August 6, 2013
    Publication date: December 5, 2013
    Applicant: Gilead Sciences, Inc.
    Inventors: Matthew Abelman, Robert H. Jiang, Jeff Zablocki
  • SUSTAINED RELEASE EYE DROP FORMULATIONS
    Publication number: 20130324481
    Abstract: This invention provides for biocompatible, biodegradable eye drop pharmaceutical formulations useful for the treatment of ocular indications. In particular, tocopherols and their esters of low water solubility, notably ?-tocopheryl acetate, are exceptional vehicles for biocompatible, nonirritating topical eye drop formulations that provide sustained release of active agents.
    Type: Application
    Filed: August 9, 2013
    Publication date: December 5, 2013
    Applicant: Ramscor, Inc.
    Inventors: Vernon G. Wong, Louis L. Wood
  • SPIROKETALS
    Publication number: 20130324596
    Abstract: The present invention relates to spiroketal compounds that are useful in methods of treating or preventing protozoal infections, parasitic infections, bacterial infections, cell proliferative disorders and anti inflammatory disorders. The spiroketal compounds are also useful as immunosuppressive agents, and also in methods of controlling pests.
    Type: Application
    Filed: May 17, 2013
    Publication date: December 5, 2013
    Applicant: ECOBIOTICS LTD
    Inventors: Paul Warren Reddell, Victoria Anne Gordon
  • PHARMACEUTICAL COMPOSITION COMPRISING TRANS-CINNAMALDEHYDE AND ITS USE IN THE TREATMENT OF INFECTIONS
    Publication number: 20130324597
    Abstract: This invention pertains to an anti-microbial, in particular anti-bacterial, more particularly against Gram?bacteria, and/or anti-fungal composition comprising as active blend trans-cinnamaldehyde and a potentiating agent, and to the potentiating agent. In particular this composition is intended for preventing and/or treating microbial infection in an animal.
    Type: Application
    Filed: December 9, 2011
    Publication date: December 5, 2013
    Applicant: SEPTEOS
    Inventor: Nicolas Tesse
  • N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF
    Publication number: 20130317000
    Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: May 21, 2013
    Publication date: November 28, 2013
    Applicants: XENON PHARMACEUTICALS INC., GENENTECH, INC
    Inventors: Sultan Chowdhury, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Qi Jia, Daniel Ortwine, Brian Safina, Shaoyi Sun, Daniel P. Sutherlin, Alla Yurevna Zenova
  • N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF
    Publication number: 20130317001
    Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: May 21, 2013
    Publication date: November 28, 2013
    Applicants: XENON PHARMACEUTICALS INC., GENENTECH, INC.
    Inventors: Jean-Christophe Andrez, Sultan Chowdhury, Shannon Marie Decker, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Qi Jia, Jun Li, Daniel F. Ortwine, Brian Safina, Tao Sheng, Shaoyi Sun, Daniel P. Sutherlin, Michael Scott Wilson, Alla Yurevna Zenova